Gamma-glutamyl carboxylase and its influence on warfarin dose

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 750-754

  King, Cristi R ^a   Deych, Elena ^a   Milligan, Paul ^a   Eby, Charles ^a   Lenzini, Petra ^a   Grice, Gloria ^b   Porche Sorbet, Rhonda M ^a   Ridker, Paul M ^c   Gage, Brian F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Algorithm; Gamma glutamyl carboxylase; Pharmacogenetics; Warfarin

Indexed keywords

VITAMIN K DEPENDENT CARBOXYLASE; WARFARIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; FEMALE; GENE FREQUENCY; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HUMAN; INDIAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOMARKERS, PHARMACOLOGICAL; CARBON-CARBON LIGASES; CLINICAL PROTOCOLS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; VENOUS THROMBOSIS; VITAMIN K; WARFARIN;

EID: 77958129007     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-11-0763     Document Type: Article

References (40)

1. FDA Approves Updated Warfarin (Coumadin) Prescribing Information: New Genetic Information May Help Providers Improve Initial Dosing Estimates of the Anticoagulant for Individual Patients. FDA News 2007 [cited August 16, 2007]; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce ments/2007/ucm108967.htm
2. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - January 2010. Safety 2010 [cited 2010 March 10]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm201100
3. Wood S. New Warfarin Labeling Reminds Physicians About Genetic Tests to Help Guide Initial Warfarin Dosing. 2007 [cited 2007 Sept 4, 2007]; Available from: http://www.medscape.com/viewarticle/561608
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
5. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
6. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270. (Pubitemid 41131718)
7. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202. (Pubitemid 40852221)
8. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Therapeut 2008; 84: 326-331.
9. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
10. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
11. Voora D, Koboldt DC, King CR, et al. A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clin Pharmacol Therapeut 2010; 87: 445-451.
12. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clin Pharmacol Therapeut 2010; 87: 459-464.
13. Scott S, Edelmann L, Kornreich R, et al. Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations. AJHG 2008; 82: 495-500.
14. Rost S, Fregin A, Koch D, et al. Compound heterozygous mutations in the gammaglutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004; 126: 546-549. (Pubitemid 39093097)
15. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (vitamin K-dependent protein-Factors II, VII, IX, and X, proteins S and C, and {gamma}-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-2635.
16. Gage BF, Eby CS. The genetics of vitamin K antagonists. Pharmacogenomics J 2004; 4: 224-225.
17. Vanakker OM, Martin L, Gheduzzi D, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 2007; 127: 581-587.
18. Zhu A, Sun H, Raymond RM, Jr., et al. Fatal hemorrhage in mice lacking gammaglutamyl carboxylase. Blood 2007; 109: 5270-5275. (Pubitemid 46890547)
19. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007; 5: 2227-2234.
20. Wang TL, Li HL, Tjong WY, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008; 396: 76-79.
21. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 2010; 8: 1018-1026.
22. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-1662.
23. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434. (Pubitemid 36407171)
24. Marsh S, King CR, Garsa AA, et al. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005; 311: 97-114.
25. King CR, Porche-Sorbet RM, Gage BF, et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008; 129: 876-883.
26. Herman D, Peternel P, Stegnar M, et al. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 782-787.
27. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
28. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
29. Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009; 10: 1905-1913.
30. Chen LY, Eriksson N, Gwilliam R, et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 2005; 106: 3673-3674. (Pubitemid 41609210)
31. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-186. (Pubitemid 46754413)
32. Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Therapeut 2005; 77: 365-372. (Pubitemid 40719265)
33. Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
34. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 700-705. (Pubitemid 40485406)
35. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159: 46-48. (Pubitemid 29044118)
36. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94. (Pubitemid 38111225)
37. Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005; 118: 137-142. (Pubitemid 40202860)
38. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984; 288: 1268-1270. (Pubitemid 14117132)
39. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150: 73-83.
40. Knowlton CH, Thomas OV, Williamson A, et al. Establishing community pharmacy- based anticoagulation education and monitoring programs. J Am Pharm Assoc 1999; 39: 368-374.